The companies have extended a commercial supply partnership for the manufacture of Sohonos (palovarotene), which is a ...

Continuing with the rare disease theme (Rare Disease Day is Feb 28), Elisabeth Gardiner of Tevard Biosciences explains in a video interview that research into ultra-rare conditions continues to yield ...

The February 2026 meeting of the EMA's Committee for Medicinal Products for Human Use (CHMP) resulted in recommendations for twelve new medicines.¹ These outcomes, which included recommendations for ...

GSK acquires 35Pharma for $950M. The primary focus is HS235, a selective PH drug reducing bleeding risk with metabolic ...

In this forward-looking whitepaper, Blue Mountain explores how agentic AI —autonomous, context-aware AI agents—could ...

FDA's Plausible Mechanism Framework streamlines individualized therapy approvals for ultra-rare diseases.

Asahi Kasei acquires Aicuris for €780M ($920M), adding anti-infective assets to its transplant and nephrology specialty pharmaceutical platform.

A: No new regulations were published in 2025 specific to data integrity. The evolving global regulatory systems do, however, ...

Innovators are increasingly focused on whether outsourced partners can help them make better decisions earlier, before ...

Using patent intelligence data from the FounderNest platform, Gonzalez highlights where small-molecule synthesis, formulation ...

In response to Marty Makary warning the US may lose the early‑stage drug development lead to China, Brian Scanlan says speed, ...

The rapid pace of digitalization has created a skills gap, necessitating that staff with traditional chemistry or biology degrees upskill in the IT sector . BioVectra addresses this by collaborating ...